The assessment of fetal brain growth in diabetic pregnancy using in utero magnetic resonance imaging. by Paddock, M. et al.
This is a repository copy of The assessment of fetal brain growth in diabetic pregnancy 
using in utero magnetic resonance imaging..
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/142284/
Version: Accepted Version
Article:
Paddock, M., Akram, R., Jarvis, D.A. orcid.org/0000-0002-0133-1771 et al. (4 more 
authors) (2017) The assessment of fetal brain growth in diabetic pregnancy using in utero 
magnetic resonance imaging. Clinical Radiology, 72 (5). 427.e1-427.e8. ISSN 0009-9260 
https://doi.org/10.1016/j.crad.2016.12.004
Article available under the terms of the CC-BY-NC-ND licence 
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
&OLQLFDO5DGLRORJ\7KHDVVHVVPHQWRIIHWDOEUDLQJURZWKLQGLDEHWLFSUHJQDQF\XVLQJLQXWHURPDJQHWLFUHVRQDQFHLPDJLQJ0DQXVFULSW'UDIW
0DQXVFULSW1XPEHU
)XOO7LWOH 7KHDVVHVVPHQWRIIHWDOEUDLQJURZWKLQGLDEHWLFSUHJQDQF\XVLQJLQXWHURPDJQHWLF
UHVRQDQFHLPDJLQJ
$UWLFOH7\SH 2ULJLQDO3DSHU
&RUUHVSRQGLQJ$XWKRU 0LFKDHO3DGGRFN
8QLYHUVLW\RI6KHIILHOG
6KHIILHOG6RXWK<RUNVKLUH81,7('.,1*'20
&RUUHVSRQGLQJ$XWKRU6HFRQGDU\
,QIRUPDWLRQ
&RUUHVSRQGLQJ$XWKRU
V,QVWLWXWLRQ 8QLYHUVLW\RI6KHIILHOG
&RUUHVSRQGLQJ$XWKRU
V6HFRQGDU\
,QVWLWXWLRQ
)LUVW$XWKRU 0LFKDHO3DGGRFN
)LUVW$XWKRU6HFRQGDU\,QIRUPDWLRQ
2UGHURI$XWKRUV 0LFKDHO3DGGRFN
5DKLP$NUDP
'HERUDK$-DUYLV
3DXO$UPLWDJH
6RRQ6RQJ
3UL\D0DGKXYUDWD
3DXO'*ULIILWKV
2UGHURI$XWKRUV6HFRQGDU\,QIRUPDWLRQ
$EVWUDFW $LP7RDVVHVVIHWDOEUDLQJURZWKRYHUWKHWKLUGWULPHVWHULQSUHJQDQWZRPHQZLWK
GLDEHWHVXVLQJLQXWHURPDJQHWLFUHVRQDQFHLPDJLQJLX05WRGHWHUPLQHLIJUHDWHU
EUDLQJURZWKRFFXUVLQW\SH7'0ZKHQFRPSDUHGWRJHVWDWLRQDO*'0GLDEHWHV
0DWHULDOVDQG0HWKRGV(DFKFRQVHQWHGSDUWLFLSDQWZDVVFDQQHGDWWKUHHIL[HGWLPHV
GXULQJWKHWKLUGWULPHVWHUXVLQJLX05SDWLHQWVZHUHDSSURDFKHGSDUWLFLSDQWV
ZHUHUHFUXLWHGDQGFRPSOHWHGDWDVHWVZHUHDQDO\VHG'LX05YROXPHGDWDVHWV
ZHUHPDQXDOO\VHJPHQWHGXVLQJVRIWZDUHWRFRQVWUXFWPRGHOVRIWKHIHWDOEUDLQIURP
ZKLFKEUDLQYROXPHVFRXOGEHFDOFXODWHG,QWHUUDWHUDQDO\VLVZDVSHUIRUPHGDQG
YROXPHGLIIHUHQFHVDQGJURZWKUDWHVZHUHFRPSDUHGEHWZHHQ7'0DQG*'0
5HVXOWV5HFUXLWPHQWSURYHGGLIILFXOWZLWKORZXSWDNHDQGKLJKDWWULWLRQUDWHV
,QWHUUDWHUDQDO\VLVUHYHDOHGH[FHOOHQWFRUUHODWLRQLQWUDFODVVFRUUHODWLRQ
FRHIILFLHQW SDQGDJUHHPHQWZLWKQRVLJQLILFDQWGLIIHUHQFHEHWZHHQ
RSHUDWRUVS 7KHUHZDVQRHYLGHQFHRILQFUHDVHGEUDLQYROXPHLQWKH7'0
JURXS*URZWKUDWHVEHWZHHQYLVLWDQGIRU7'0DQG*'0ZHUHQRWVLJQLILFDQWO\
GLIIHUHQWS 
&RQFOXVLRQ7'0EUDLQYROXPHVZHUHQRWVLJQLILFDQWO\ODUJHUWKDQ*'0YROXPHVDQG
WKHUHZDVQRVLJQLILFDQWGLYHUJHQFHRIEUDLQJURZWKRYHUWKHWKLUGWULPHVWHU
&RQVWUXFWLQJYROXPHPRGHOVIURP'LX05DFTXLVLWLRQVLVDQRYHOWHFKQLTXHWKDWFDQ
EHXVHGWRDVVHVVIHWDOEUDLQJURZWK1RVSHFLDOLVWVRIWZDUHRUNQRZOHGJHLVUHTXLUHG
/DUJHUVWXGLHVDWWHPSWLQJWRUHFUXLWSUHJQDQWZRPHQLQWKHODWHUVWDJHVRISUHJQDQF\
VKRXOGHPSOR\PXOWLFHQWUHUHFUXLWPHQWWRRYHUFRPHUHFUXLWPHQWGLIILFXOWLHVDQGKLJK
DWWULWLRQUDWHV
Powered by Editorial Manager¨ and ProduXion Manager¨ from Aries Systems Corporation
The assessment of fetal brain growth in diabetic pregnancy using in utero magnetic 
resonance imaging 
 
Michael Paddock a,*, Rahim Akram b, Deborah A Jarvis a, Paul Armitage a, Soon Song c, Priya 
Madhuvrata d, Paul D Griffiths a 
 
a Academic Unit of Radiology, University of Sheffield, Royal Hallamshire Hospital, Sheffield, 
S10 2JF, UK 
b The Medical School, The University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK 
c Department of Diabetes and Endocrinology, Northern General Hospital, Sheffield, S5 7AU, 
UK 
d Department of Obstetrics & Gynaecology, Sheffield Teaching Hospitals NHS Foundation 
Trust, Sheffield, S10 2JF, UK 
 
*Guarantor and correspondent: Dr Michael Paddock, Academic Unit of Radiology, 
University of Sheffield, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK 
Telephone: +44 114 271 1643. Facsimile: +44 114 271 1714 
E-mail: michael.paddock@doctors.org.uk 
 
Funding information 
 
This study was funded with the aid of a grant from the Royal College of Radiologists 
and the British Society of Neuroradiologists. The funders had no involvement in the study 
design, collection, analysis and interpretation of data, the writing of the report or in the decision 
to submit the article for publication. The study was sponsored by the University of Sheffield 
and Sheffield Teaching Hospitals NHS Foundation Trust. 
 
Conflict of interest 
 
The authors declare no conflict of interest. 
 
Submission declaration 
 
This article has not been published previously and is not under consideration 
elsewhere. Its publication is approved by all authors and explicitly by the responsible 
authorities where the work was carried out, and if accepted, will not be published elsewhere. 
 
Acknowledgements 
 
We would like to thank Dr Dinesh Selvarajah for his insights throughout the execution 
of this study. We are indebted to the specialist diabetes midwifery team at Sheffield Teaching 
Hospital NHS Foundation Trust, in particular Rebecca Bustani, Kimberley Clark and Frances 
Crawley, for their help with patient recruitment. 
7LWOH3DJH
Author contributions 
 
1. guarantor of integrity of the entire study ± MP 
2. study concepts and design ± MP, SS, PA, PDG 
3. literature research ± MP, RA 
4. clinical studies ± PDG 
5. experimental studies / data analysis ± MP, PDG 
6. statistical analysis ± MP, RA, DJA, PDG 
7. manuscript preparation ± MP 
8. manuscript editing ± MP, RA, DJA, PA, SS, PM, PDG 
$XWKRU&RQWULEXWLRQV
ABSTRACT 
 
Aim: To assess fetal brain growth over the third trimester in pregnant women with diabetes 
using in utero magnetic resonance imaging (iuMR) to determine if greater brain growth occurs 
in type 1 (T1DM) when compared to gestational (GDM) diabetes.  
 
Materials and Methods: Each consented participant was scanned at three fixed times during 
the third trimester using iuMR. 157 patients were approached, 48 participants were recruited 
and 36 complete data sets were analysed. 3D iuMR volume data sets were manually 
segmented using software to construct models of the fetal brain from which brain volumes 
could be calculated. Inter-rater analysis was performed, and volume differences and growth 
rates were compared between T1DM and GDM. 
 
Results: Recruitment proved difficult with low uptake and high attrition rates (77.1%). Inter-
rater analysis revealed excellent correlation (intraclass correlation coefficient=0.93, p<0.001) 
and agreement with no significant difference between operators (p=0.194). There was no 
evidence of increased brain volume in the T1DM group. Growth rates between visit 1 and 3 
for T1DM and GDM were not significantly different (p=0.095). 
 
Conclusion: T1DM brain volumes were not significantly larger than GDM volumes and there 
was no significant divergence of brain growth over the third trimester. Constructing volume 
models from 3D iuMR acquisitions is a novel technique that can be used to assess fetal brain 
growth. No specialist software or knowledge is required. Larger studies attempting to recruit 
pregnant women in the later stages of pregnancy should employ multicentre recruitment to 
over-come recruitment difficulties and high attrition rates. 
$EVWUDFW
 1 
Introduction 1 
 2 
 Diabetes mellitus (DM) occurs in 2±5% of pregnant women in England and 3 
Wales1 of which approximately 87% have gestational diabetes (GDM), 8% type 1 4 
diabetes (T1DM) and 5% type 2 diabetes (T2DM).2 Pre-existing diabetes (T1DM and 5 
T2DM) is associated with a number of risks to both mother and fetus including 6 
miscarriage, pre-eclampsia, preterm labour, malformations and stillbirth.3-5 The risks 7 
of perinatal complications in T1DM pregnancies are quoted as two to five times greater 8 
than that of the general population,6 even in the presence of good glycaemic control 9 
during pregnancy.7 Inadequate glycaemic control is associated with a higher risk of 10 
recurrent miscarriage, stillbirth and congenital anomalies8,9 and is the most important 11 
factor contributing to the increased risk of fetal and infant death in the absence of 12 
congenital malformations.10  13 
It is well established that women with DM tend to have larger fetuses and babies 14 
(macrosomia) when compared to non-diabetic women.5 Whilst the overall size of a 15 
fetus can be measured reliably ante-natally on ultrasonography, robust quantification 16 
of brain volume is considerably more difficult, if not impossible, with that technique. 17 
Surrogate measurements of fetal brain size in the literature are made by measuring 18 
the biparietal diameter (BPD) on ultrasound. It has been shown that BPD 19 
measurements are greater in those fetuses whose mothers have diabetes when 20 
compared to normal pregnancies.11,12 The main problem is that there may be a 21 
disconnect between skull growth and brain growth; the BPD, as a subjective/operator 22 
dependant ultrasound assessment, is a poor indicator of µbrain size¶By comparison, 23 
in utero magnetic resonance (iuMR) imaging provides a comprehensive cross-24 
sectional evaluation which has been shown to be superior in the assessment of the 25 
0DQXVFULSW
 2 
fetal brain and the detection of abnormalities.13-16 Recent advances in iuMR imaging, 26 
in particular, rapid T2 weighted three-dimensional (3D) volume sequences, have 27 
allowed detailed assessment of the fetal brain,17 facilitating estimation of brain volume 28 
(distinct from skull measurements) and the ability to assess brain maturity in terms of 29 
gyration/sulcation. 30 
No data currently exists regarding brain volumes and the rate of fetal brain 31 
growth during third trimester pregnancy in DM. In this study, we assessed third 32 
trimester fetal brain growth (volume, as measured by iuMR) in women with DM to 33 
assess when, and if, differential brain growth occurs. 34 
 35 
Materials and Methods 36 
 37 
Participants and recruitment 38 
 39 
 The study population comprised of women with diabetes (T1DM, T2DM and 40 
GDM) who attended specialist antenatal clinics and workshops at our institution. 41 
Inclusion criteria were: maternal age >16 years at time of recruitment; normal anomaly 42 
ultrasound scan at 20 gestational weeks (GW); singleton pregnancy; between 20 and 43 
28 GW at the time of recruitment. Exclusion criteria were: inability to speak fluent 44 
English (therefore unable to provide independent informed consent); contraindications 45 
to iuMR imaging. Potential participants were given an information leaflet on iuMR 46 
scanning, were contacted after 48 hours and offered three sequential MR 47 
examinations at GW 28±1 (visit 1), 31±1 (visit 2) and 34±1 (visit 3). Complete data 48 
sets were excluded if they fell outside these predefined timings. Recruitment occurred 49 
over a 20-month period from 2013 to 2015. Local institutional ethical approval was 50 
 3 
obtained EXWGLGQRWDOORZIRUFRQVHFXWLYHVFDQQLQJRIµQRUPDO¶QRQ-diabetic pregnant 51 
women. As such, pregnant women with GDM acted as a µdisease control¶ given that 52 
they are much less likely to have large babies compared to women with pre-exiting 53 
diabetes.18-21 Informed consent was obtained during the first pre-scan discussion in 54 
addition to formal MR safety screening which was performed at least twice prior to 55 
scanning. 56 
 57 
MR imaging 58 
 59 
 All iuMR imaging was performed on the same whole body 1.5T GE HDx 60 
(General Electric Healthcare, Milwaukee, WI) scanner using an eight-channel cardiac 61 
phased-array coil. No maternal sedation was used. Following routine imaging of the 62 
fetal brain, 3D volumetric data sets were acquired using the Fast Imaging Employing 63 
Steady-state Acquisition (FIESTA) sequence in the axial plane relative to the fetal 64 
brain.17 Imaging parameters were: 4-5 ms minimum repetition time (TR); 2-3 ms 65 
minimum echo time (TE); refocusing flip angle of 60¡; 0.75 number of excitations 66 
(NEX); field of view (FOV) 340 x 270 mm; matrix size of 320 x 256 mm. Partition 67 
thickness was 1.8-2.2 mm with 28-32 scan locations per slab dependent on fetal brain 68 
size. In order to allow full coverage of the fetal brain with maximal resolution, the 69 
section thickness or number of scan locations was adjusted and achieved in a 70 
timeframe conducive to a maternal breath-hold (20-23 s).  71 
 $UHSRUWZDVLVVXHGIRUDOOVFDQVE\DQHXURUDGLRORJLVW3'*RYHU\HDUVRI72 
IHWDO QHXURUDGLRORJ\ H[SHULHQFH VWDWLQJ WKDW WKH SURFHGXUH ZDV SHUIRUPHG IRU73 
UHVHDUFKSXUSRVHV,IQREUDLQDEQRUPDOLW\ZDVVKRZQµQRXQH[SHFWHGDEQRUPDOLWLHV¶74 
ZDVUHSRUWHG,IWKHUHZDVDIXUWKHULQWUDFUDQLDODEQRUPDOLW\DIXOOFOLQLFDOUHSRUWZDV75 
 4 
SURYLGHGGLUHFWO\ WR WKHSDWLHQW¶VREVWHWULFLDQ(DFKSDUWLFLSDQWZDV LQYLWHGEDFN IRU76 
IXUWKHUVFDQVDFFRUGLQJWRWKHSUHGHILQHGWLPHOLPLWVDERYHKRZHYHUWKH\ZHUHXQGHU77 
QR REOLJDWLRQ WR GR VR $ FRPSOHWH GDWD VHW FRPSULVHG RI WKUHH FRQVHFXWLYH LX0578 
VFDQV 79 
 80 
3RVWSURFHVVLQJDQGVWDWLVWLFDODQDO\VLV 81 
 82 
 $OOLPDJLQJZDVDQRQ\PLVHGUHIRUPDWWHGWUDQVIHUUHGRQWRDGHVNWRSSHUVRQDO83 
FRPSXWHU DQG ORDGHG LQWR WKUHHGLPHQVLRQDO ' UHFRQVWUXFWLRQ VRIWZDUH84 
ZZZVOLFHURUJ $V VKRZQ LQ )LJ DG WKH YHQWULFOHV FHUHEUDO KHPLVSKHUHV85 
FHUHEHOOXPDQGH[WUDFUDQLDOFHUHEURVSLQDOIOXLGYROXPHZHUHGHOLQHDWHGE\KDQGRQ86 
HYHU\D[LDOVOLFHLQWKHYROXPHWULF05DFTXLVLWLRQE\WUDLQHGRSHUDWRUVLQYROYHGLQWKH87 
VWXG\DAJ, experienced operator {operator 1}; RA, newly trained {operator 2}7KH88 
YROXPHWULF GDWD IRU TXDOLWDWLYH DQDO\VLV ZHUH JHQHUDWHG IURP VXUIDFH UHQGHUHG '89 
PRGHOVIRUHDFKDUHDRIGHOLQHDWHGDQDWRPLFDOLQWHUHVWDVVKRZQLQ)LJHDQGI90 
7KLVPHWKRGLVEDVHGRQSUHYLRXVO\SXEOLVKHGZRUNIURPRXULQVWLWXWLRQ 91 
Fourteen data sets from visit 1 were measured separately by the two operators 92 
for inter-rater analysis (all seven T1DM and seven randomly selected GDM cases). 93 
InGHSHQGHQW WWHVWV ZHUH XVHG WR FRPSDUH percentage differences and intraclass 94 
correlation coefficient (ICC) was calculated to assess correlation. A Bland-Altman plot 95 
was constructed to assess agreement, variability and bias. 96 
7RWDO SDUHQFK\PDO EUDLQ YROXPH 73%9 ZDV GHULYHG IURP WKH GLIIHUHQFH97 
between the total brain volume (both cerebral hemispheres and cerebellum) and the 98 
internal (ventricular) cerebrospinal fluid volumeWKH73%9'PRGHOLVVKRZQLQ)LJ99 
I,QGHSHQGHQWWWHVWVZHUHHPSOR\HGWRHYDOXDWHDQ\GLIIHUHQFHVLQIHWDOEUDLQJURZWK100 
 5 
EHWZHHQ ERWK JURXSV 7KH GLIIHUHQFH EHWZHHQ LQGLYLGXDO IHWDO EUDLQ YROXPHV ZHUH101 
FDOFXODWHGEHWZHHQYLVLWVDQGDQGGLYLGHGE\WKHQXPEHURIZHHNVZHHNVWR102 
FDOFXODWHUDWHVRIEUDLQJURZWK. SZDVFRQVLGHUHGVWDWLVWLFDOO\VLJQLILFDQWDQGWKH103 
SYDOXHVZHUHVLGHGWRSURYLGHPRUHSRZHUWRGHWHFWDQHIIHFW6WDWLVWLFDODQDO\VLV104 
ZDVSHUIRUPHGXVLQJ63666366&KLFDJR,/ 105 
 106 
Results 107 
 108 
Over the 20-month recruitment period, 157 pregnant women with DM were 109 
approached for potential recruitment (106 with GDM, 22 with T1DM and 29 with 110 
T2DM). Of those, 48 gave consent for participation (age range 21 to 45 years). 12 111 
incomplete data sets were excluded leaving 36 complete data sets available for 112 
analysis: Q *'0DJH UDQJH WR\HDUVQ 7'0DJH UDQJH WR113 
\HDUVQ 7'07KHUHFUXLWPHQWDQGDWWULWLRQUDWHVDUHRXWOLQHGLQ)LJ 114 
2QH IHWXV IURP D SUHJQDQW ZRPDQ ZLWK 7'0 KDG XQLODWHUDO PLOG115 
YHQWULFXORPHJDO\ GHILQHG E\ WULJRQH PHDVXUHPHQWV PP GLDJQRVHG RQ YLVLW 116 
LX05LPDJLQJ WKHWULJRQHRI WKH OHIW ODWHUDOYHQWULFOHPHDVXUHGPPDQGWKHULJKW117 
WULJRQHPHDVXUHGPP7KHYHQWULFXORPHJDO\SHUVLVWHGWKURXJKRXWWKHVWXG\SHULRG118 
PHDVXULQJPPRQYLVLWDQGPPRQYLVLW LX05LPDJLQJ1RRWKHUVWUXFWXUDO119 
EUDLQDEQRUPDOLWLHVZHUHVKRZQ 120 
Inter-rater analysis is shown in Table 1. No statistically significant difference 121 
was found: t(26)=0.88, p=0.194 (95% confidence interval (CI), -5.52 to 13.78). The 122 
average measure ICC was 0.93, p<0.001 (95% CI, 0.643 to 0.981). The corresponding 123 
Bland-Altman plot (Fig. 3) illustrates that all values lie within the 95% confidence limits 124 
 6 
with a degree of bias towards the results of the more experienced operator 1 (10 data 125 
points lie above zero). 126 
Fig. 4 illustrates the distribution of TPBV at each visit. The visit 1 GDM TPBV 127 
was statistically significantly higher than T1DM (p=0.020). The possible relevance of 128 
this apparently spurious result is described below. There was no statistically significant 129 
difference between GDM and T1DM brain volumes at visit 2 (p=0.456) and visit 3 130 
(p=0.053). The growth rates (cm3/week ± standard deviation) between visit 1 and 3 131 
were not statistically significantly different (GDM, 17.39 ± 0.64; T1DM, 18.24 ± 3.15; 132 
t(33.8)=1.34, p=0.095). 133 
 134 
Discussion 135 
 136 
This study highlights the difficulty in recruiting pregnant women with DM into 137 
iuMR studies, relevant when attempting to perform a study from a single centre. We 138 
found that it was easier to recruit women from workshops that were less time-139 
pressured when compared with busy clinics. Over the 20-month recruitment period, 140 
157 potential participants were approached. After formal discussion and allowing 141 
sufficient time for consideration, the rate of consented participants was low (n=48/157, 142 
30.6%). Once consented, the retention rate was relatively high (n=36/48, 75%); 143 
reasons for incomplete data sets are provided in Fig. 2. The overall attrition rate from 144 
approach to completion was far lower than expected (n=36/157, 77.1%) and only 36 145 
complete data sets were acquired, i.e. less than 2 per month. 146 
Participants were not asked about their reasons for withdrawing/not 147 
attending/not wanting to book further scans but some offered reasons without 148 
prompting: childcare issues; previous miscarriage, worried about the long term effects 149 
 7 
of MR; claustrophobic, could not tolerate further scans; time commitments as still 150 
working; too many other appointments. Some commented that a significant attraction 151 
of this study was direct funding/reimbursement of all travel expenses. Given that 152 
recruitment and retention from this patient group is difficult, the research design of any 153 
larger study would need to be dynamic and flexible. Furthermore, formal qualitative 154 
assessment should be undertaken through formal patient and public information (PPI) 155 
engagement with specific reference to the acceptability of consecutive iuMR scanning 156 
in third trimester pregnancies to address the practicality and viability of a larger scale 157 
study. 158 
The high proportion of pregnant women with GDM who were approached, 159 
consented and retained for final analysis is similar to the reported prevalence in the 160 
general population.1 The difficulties of recruiting pregnant women into research 161 
studies is well documented,23-26 particularly during the third trimester with high attrition 162 
rates also reported.27 This was the first study from our unit attempting to recruit 163 
pregnant women for consecutive third trimester iuMR scanning, which to our 164 
knowledge no reported study has previously attempted. It is clear that future studies 165 
attempting to recruit women for consecutive iuMR third trimester scanning would need 166 
to employ multicentre recruitment to allow for potentially suboptimal participation and 167 
high attrition, in addition to funding travel expenses. The links forged from previous 168 
multicentre work co-ordinated at our institution would facilitate this process.28 169 
Inter-rater analysis allows us to assess the reliability (inherent repeatability) and 170 
precision of the 3D volumetric measurements between operators so that our results 171 
have external validity (generalisability). All inter-rater percentage differences between 172 
both operators varied by less than ±10%, with half varying by less than ±5% and there 173 
was excellent correlation (ICC 0.93, p<0.001). The Bland-Altman plot (Fig. 3) 174 
 8 
demonstrated that the mean differences became slightly larger as the mean volume 175 
increased. However, given the small sample size (n=14) and with all results within the 176 
narrow limits of agreement, any bias or variability demonstrated by Operator 1 is very 177 
unlikely to be clinically or practically significant which is important when considering 178 
the generalisability of this technique. Furthermore, we demonstrated no statistically 179 
significant difference between the volume data measurements between both 180 
operators (p=0.194). 181 
Factors contributing to variability or bias centred around the segmentation 182 
process and accurate delineation of structures at µtrue¶ interfaces, i.e. parenchymal-183 
cerebrospinal fluid interface, noted to be most difficult at the trigonal ventricular choroid 184 
plexus-periventricular white matter interface. Other factors included: fetal and/or 185 
maternal movement artefact resulting in poor image quality; subjective differences in 186 
contrast and brightness settings which can be altered at any time during segmentation; 187 
changes in ambient lighting; visual and muscular fatigue when segmenting older 188 
gestational fetal brains because of the more complex sulcation pattern. 189 
Previous studies have demonstrated that neonates born to diabetic mothers 190 
have larger head circumferences when compared to those born to non-diabetic 191 
mothers,29 interpreted to indicate that they would have larger brains. Our assumption 192 
before this study commenced was that T1DM fetuses would have larger brain volumes 193 
when compared to GDM/normal brains, although we did not know at what gestational 194 
age this difference would become apparent. In spite of the lack of supporting data from 195 
antenatal ultrasound, we predicted that any statistically significant differences in brain 196 
volume would be apparent by visit 3 (34±1 GW) given that maximal neural growth and 197 
development occurs during this period.30 Brain volumes in fetuses of women with 198 
T1DM however were not significantly larger than those with GDM and there was no 199 
 9 
significant difference in the rate of growth between 28 to 34 GW. It is likely therefore 200 
that the divergence in brain growth could be found beyond 35 weeks given the larger 201 
head size in T1DM neonates at birth.11,29 Contrary to our expectation, the T1DM mean 202 
TPBV at visit 1 (28±1 GW) was statistically significantly smaller than that of GDM 203 
(p=0.020). There is no supporting evidence in the literature that BPD measurements 204 
on ultrasound are smaller in fetuses of mothers with T1DM than their GDM 205 
counterparts, and given the small sample size (n=7 in the T1DM group), this is 206 
probably a spurious result. This time point (28±1 GW) could be further re-examined in 207 
a larger study to determine the time point at which differential brain growth occurs. 208 
Recent literature has debated the impact of endothelial dysfunction on umbilical 209 
arteries in pre-existing DM.31,32 Blood flow is more critical for organ development 210 
earlier in pregnancy and the subsequent dysregulation in umbilical blood flow may 211 
result in underdevelopment of the fetal brain. It is possible that this is more pronounced 212 
in brains of fetuses whose mothers have T1DM, such that from a metabolic 213 
perspective there is more physiological µcatching up¶ to do in utero which is 214 
compensated for in later pregnancy 36 GW). This may explain why those born to 215 
mothers with DM have bigger heads and are larger than their non-diabetic 216 
counterparts. Evidently, the underlying physiological mechanism warrants further 217 
investigation in addition to an assessment of fetal brain growth not captured in this 218 
study. 219 
As previously discussed, initial recruitment proved difficult and many data sets 220 
remained incomplete due to patient withdrawal. In order to recruit sufficient numbers, 221 
the list of possible participants was discussed with the specialist diabetes midwifery 222 
team at the start of each specialist clinic or workshop. Given the time and expense 223 
involved in performing 3 iuMR scans, we sought to recruit patients invested in 224 
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completing all 3 scans in order to obtain complete data sets. As such, those known to 225 
the local service with a history of non-compliance, who frequently missed 226 
appointments and with complex social issues were deemed not appropriate to 227 
approach. However, even in spite of this, some of the latter recruited participants still 228 
did not attend all three scans or withdrew. 229 
The sample size (n=36) was not large enough to capture any results that were 230 
likely to be that clinically meaningful however this data can be used to power a larger 231 
study. As described above, an assessment of late third trimester diabetic pregnancies 232 
(>35 GW) may elucidate the point at which differential brain growth occurs. A larger 233 
study should encompass the influence of maternal factors on brain growth and 234 
maturation including: weight (body mass index); type and/or combination of 235 
management of diabetes in pregnancy (diet controlled, oral hypoglycaemics, insulin); 236 
quality of glycaemic control, particularly considering that even in the presence of an 237 
overall good level of glycaemic control the frequency of macrosomia remains high.33,34 238 
Alongside the 3D iuMR data sets, the 3D surface rendering of the fetal brain22 239 
could be used to estimate the gestational age of the fetus based on its sulcation 240 
pattern, comparing to standard atlases and actual gestational age. An assessment of 241 
brain maturation rate between the different types of diabetes could also be performed 242 
which would allow further development of a fetal brain maturation database and 243 
subsequent validation of a fetal brain maturation scoring system building upon 244 
previously published work in this area.35  245 
The novel techniques described could be expanded to assess the effect of 246 
conditions known to affect fetal growth during pregnancy: placental insufficiency; intra-247 
uterine growth restriction in both singleton and multiple pregnancies; baseline growth 248 
differences in twin pregnancy; twin-to-twin transfusion syndrome. 249 
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 250 
Conclusion 251 
 252 
We have shown that 3D volumetric modelling from manually segmented 3D 253 
iuMR acquisition is a reliable and reproducible technique. Users with no prior 254 
knowledge of the software or technique can be trained to use the programme to 255 
produce reliable results. The method does not require specialist computer software 256 
(3D slicer is freely available) or specialist knowledge to operate. This technique can 257 
be implemented in the clinical environment with wide-range applicability for use by any 258 
healthcare professional. With regard to fetal brain growth and maturation, it is clear 259 
that more work in this area is needed and that larger studies would need to employ 260 
multicentre recruitment and encompass a flexible research design. 261 
 262 
 263 
References 264 
 265 
1. NICE. Diabetes in pregnancy: management from preconception to the 266 
postnatal period (NG3). https://www.nice.org.uk/guidance/ng3 (Accessed: 5 267 
July 2016). Published: February 2015. Last updated: August 2015. 268 
2. Magon N, Chauhan M. Pregnancy in Type 1 Diabetes Mellitus: How Special 269 
are Special Issues? N Am J Med Sci. 2012; 4(6):250-256. 270 
3. Hawthorne G, Robson S, Ryall EA, Sen D, Roberts SH, Ward Platt MP. 271 
Prospective population based survey of outcome of pregnancy in diabetic 272 
women: results of the Northern Diabetic Pregnancy Audit, 1994. British 273 
Medical Journal. 1997; 315(7103):279-281. 274 
4. Negrato CA, Mattar R, Gomes MB. Adverse pregnancy outcomes in women 275 
with diabetes. Diabetol Metab Syndr. 2012; 4(1):41. 276 
5. Nold JL, Georgieff MK. Infants of diabetic mothers. Pediatric clinics of North 277 
America. 2004; 51(3):619-637, viii. 278 
6. Colstrup M, Mathiesen ER, Damm P, Jensen DM, Ringholm L. Pregnancy in 279 
women with type 1 diabetes: have the goals of St. Vincent declaration been 280 
met concerning foetal and neonatal complications? The journal of maternal-281 
fetal & neonatal medicine : the official journal of the European Association of 282 
Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, 283 
the International Society of Perinatal Obstet. 2013; 26(17):1682-1686. 284 
 12 
7. Evers IM, de Valk HW, Visser GH. Risk of complications of pregnancy in 285 
women with type 1 diabetes: nationwide prospective study in the Netherlands. 286 
Bmj. 2004; 328(7445):915. 287 
8. Azar M, Lyons TJ. Management of pregnancy in women with type 1 diabetes. 288 
Minerva endocrinologica. 2013; 38(4):339-349. 289 
9. Allen VM, Armson BA, Wilson RD, et al. Teratogenicity associated with pre-290 
existing and gestational diabetes. Journal of obstetrics and gynaecology 291 
Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 292 
2007; 29(11):927-944. 293 
10. Tennant PW, Glinianaia SV, Bilous RW, Rankin J, Bell R. Pre-existing 294 
diabetes, maternal glycated haemoglobin, and the risks of fetal and infant 295 
death: a population-based study. Diabetologia. 2014; 57(2):285-294. 296 
11. Wong SF, Lee-Tannock A, Amaraddio D, Chan FY, McIntyre HD. Fetal growth 297 
patterns in fetuses of women with pregestational diabetes mellitus. Ultrasound 298 
Obstet Gynecol. 2006; 28(7):934-938. 299 
12. Murata Y, Martin CB, Jr. Growth of the biparietal diameter of the fetal head in 300 
diabetic pregnancy. Am J Obstet Gynecol. 1973; 115(2):252-256. 301 
13. Morris JE, Rickard S, Paley MN, Griffiths PD, Rigby A, Whitby EH. The value 302 
of in-utero magnetic resonance imaging in ultrasound diagnosed foetal 303 
isolated cerebral ventriculomegaly. Clinical radiology. 2007; 62(2):140-144. 304 
14. Rich P, Jones R, Britton J, Foote S, Thilaganathan B. MRI of the foetal brain. 305 
Clinical radiology. 2007; 62(4):303-313. 306 
15. Williams F, Griffiths PD. The diagnosis of hemimegalencephaly using in utero 307 
MRI. Clinical radiology. 2014; 69(6):e291-297. 308 
16. Craven I, Bradburn MJ, Griffiths PD. Antenatal diagnosis of agenesis of the 309 
corpus callosum. Clinical radiology. 2015; 70(3):248-253. 310 
17. Griffiths PD, Jarvis D, McQuillan H, Williams F, Paley M, Armitage P. MRI of 311 
the foetal brain using a rapid 3D steady-state sequence. The British journal of 312 
radiology. 2013; 86(1030):20130168. 313 
18. Ehrenberg HM, Mercer BM, Catalano PM. The influence of obesity and 314 
diabetes on the prevalence of macrosomia. Am J Obstet Gynecol. 2004; 315 
191(3):964-968. 316 
19. Lawlor DA, Fraser A, Lindsay RS, et al. Association of existing diabetes, 317 
gestational diabetes and glycosuria in pregnancy with macrosomia and 318 
offspring body mass index, waist and fat mass in later childhood: findings from 319 
a prospective pregnancy cohort. Diabetologia. 2010; 53(1):89-97. 320 
20. Jolly MC, Sebire NJ, Harris JP, Regan L, Robinson S. Risk factors for 321 
macrosomia and its clinical consequences: a study of 350,311 pregnancies. 322 
Eur J Obstet Gynecol Reprod Biol. 2003; 111(1):9-14. 323 
21. Ehrenberg HM, Durnwald CP, Catalano P, Mercer BM. The influence of 324 
obesity and diabetes on the risk of cesarean delivery. Am J Obstet Gynecol. 325 
2004; 191(3):969-974. 326 
22. Jarvis DA, Armitage P, Dean A, Griffiths PD. Surface reconstructions of foetal 327 
brain abnormalities using ultrafast steady state 3D acquisitions. Clinical 328 
radiology. 2014; 69(10):1084-1091. 329 
23. Sadeghi A, Sirati-Nir M, Ebadi A, Aliasgari M, Hajiamini Z. The effect of 330 
progressive muscle relaxation on pregnant women's general health. Iran J 331 
Nurs Midwifery Res. 2015; 20(6):655-660. 332 
 13 
24. Ekstrom EC, Hyder SM, Chowdhury AM, et al. Efficacy and trial effectiveness 333 
of weekly and daily iron supplementation among pregnant women in rural 334 
Bangladesh: disentangling the issues. Am J Clin Nutr. 2002; 76(6):1392-1400. 335 
25. Mukhopadhyay A, Bhatla N, Kriplani A, Agarwal N, Saxena R. Erythrocyte 336 
indices in pregnancy: effect of intermittent iron supplementation. Natl Med J 337 
India. 2004; 17(3):135-137. 338 
26. Ridwan E, Schultink W, Dillon D, Gross R. Effects of weekly iron 339 
supplementation on pregnant Indonesian women are similar to those of daily 340 
supplementation. Am J Clin Nutr 1996; 884-890. Available at: 341 
http://www.ncbi.nlm.nih.gov/pubmed/8644682. Accessed 6, 63. 342 
27. Foulon S, Greacen T, Pasquet B, et al. Predictors of Study Attrition in a 343 
Randomized Controlled Trial Evaluating a Perinatal Home-Visiting Program 344 
with Mothers with Psychosocial Vulnerabilities. PLoS One. 2015; 345 
10(11):e0142495. 346 
28. Griffiths PD. On behalf of the MERIDIAN Study Group. Protocol 11PRT/2491: 347 
Magnetic Resonance Imaging to Enhance the Diagnosis of Fetal 348 
Developmental Brain Abnormalities in Utero (MERIDIAN) 349 
(ISRCTN27626961). http://www.thelancet.com/protocol-reviews/11PRT-2491 350 
(Accessed: 5 July 2016). Published: March 2011. 351 
29. Persson M, Pasupathy D, Hanson U, Norman M. Birth size distribution in 352 
3,705 infants born to mothers with type 1 diabetes: a population-based study. 353 
Diabetes Care. 2011; 34(5):1145-1149. 354 
30. Linderkamp O, Janus L, Linder R, Skoruppa DB. Time Table of Normal Foetal 355 
Brain Development. Int. J. Prenatal and Perinatal Psychology and Medicine. 356 
2009; 21(1/2):4-16. 357 
31. Li J, Chen YP, Dong YP, et al. The impact of umbilical blood flow regulation 358 
on fetal development differs in diabetic and non-diabetic pregnancy. Kidney 359 
Blood Press Res. 2014; 39(4):369-377. 360 
32. Vambergue A, Fajardy I. Consequences of gestational and pregestational 361 
diabetes on placental function and birth weight. World J Diabetes. 2011; 362 
2(11):196-203. 363 
33. Lepercq J, Taupin P, Dubois-Laforgue D, et al. Heterogeneity of fetal growth 364 
in type 1 diabetic pregnancy. Diabetes Metab. 2001; 27(3):339-344. 365 
34. Wong SF, Chan FY, Oats JJ, McIntyre DH. Fetal growth spurt and 366 
pregestational diabetic pregnancy. Diabetes Care. 2002; 25(10):1681-1684. 367 
35. Vossough A, Limperopoulos C, Putt ME, et al. Development and validation of 368 
a semiquantitative brain maturation score on fetal MR images: initial results. 369 
Radiology. 2013; 268(1):200-207. 370 
 371 
 372 
 373 
 374 
 375 
 376 
 377 
 14 
Figures Legends 378 
 379 
Figure 1. An example of the manual segmentation and construction of brain models 380 
from which the total parenchymal brain volume (TPBV) was calculated. Figures 1a ± 381 
1d are the same axial slice from a 3D FIESTA acquisition of a 29 week fetus from a 382 
woman with gestational diabetes. (a) Delineation of the internal cerebrospinal fluid 383 
(ventricular) volume (blue), (b) right hemisphere (gold), (c) left hemisphere (cream) 384 
and (d) external cerebrospinal fluid (extracranial) volume (red). The cerebellum is also 385 
segmented (green, not shown in these images). Segmentation is performed on all 386 
slices in the volume acquisition and models of the ventricles (e) and whole brain (f) 387 
are created. The models generate quantitative volumetric data for each area. The 388 
TPBV is derived from the difference between the total brain volume (both cerebral 389 
hemispheres and cerebellum) and the internal (ventricular) cerebrospinal fluid volume. 390 
 391 
 392 
Figure 2. Flowchart outlining recruitment and attrition. GDM=gestational diabetes 393 
mellitus. T1DM=type 1 diabetes mellitus. T2DM=type 2 diabetes mellitus. 394 
 395 
 396 
Figure 3. Bland-Altman plot of differences between operator 1 (DAJ, experienced) 397 
and 2 (RA, newly trained). Solid black line=mean. Dashed lines=95% limits of 398 
agreement. 399 
 400 
 401 
 402 
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Figure 4. Box-and-whisker plot illustrating the total brain parenchymal volume (TPBV) 403 
over the course of the third trimester at each visit by type of diabetes mellitus. Visit 1 404 
(gestational weeks)=28±1. Visit 2=31±1. Visit 3=34±1. The visit 1 GDM TPBV was 405 
significantly higher than T1DM (t(34)=2.15, p=0.020, 95% confidence interval (CI) -406 
22.52 to -0.62). There was no significant difference between GDM and T1DM brain 407 
volumes at visit 2 (t(34)=0.11, p=0.456, 95% CI -17.96 to 16.09) and visit 3 (t(34)=1.17, 408 
p=0.053, 95% CI -17.34 to 1.71). 409 
 410 
 411 
Table Legend 412 
 413 
Table 1. Percentage differences for 14 selected volumes (seven T1DM and seven 414 
randomly selected GDM cases) from visit 1 (28±1 gestational weeks) between two 415 
operators involved in the study. Operator 1=DAJ. Operator 2=RA. 416 
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HIGHLIGHTS 
 
? No differential brain growth occurs over the third trimester of diabetic pregnancy 
? Manual segmentation of 3D iuMR acquisitions requires no specialist knowledge 
? 3D volume modelling of the fetal brain is a reliable and reproducible technique 
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